Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2019—ARUP Laboratories and Techcyte, a developer of artificial intelligence–based image analysis solutions for the diagnostics industry, have developed an AI-augmented ova and parasite detection tool.
October 2019—Myriad Genetics announced publication of results from a study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer (Canter DJ, et al. Prostate Cancer Prostatic Dis. Epub ahead of print June 27, 2019). The pooled analysis included 1,062 men with localized prostate cancer who were definitively treated with surgery (n = 800) or radiation (n = 262). The primary objective was to evaluate the ability of the Prolaris test (CCP score)
October 2019—Randox Laboratories announced that the NGSP has awarded it with a manufacturer certification for direct HbA1c testing on three of the company’s clinical chemistry analyzers, the RX Modena, RX Imola, and RX Daytona+.
October 2019—Biodesix (Boulder, Colo.) announced that it will acquire Oncimmune’s U.S. operations, which include a CLIA lab in De Soto, Kan., and the company’s incidental pulmonary nodule malignancy test, Early-CDT Lung.
October 2019—The U.S. Federal Bureau of Investigation has approved Thermo Fisher Scientific’s Applied Biosystems Precision ID System mtDNA analysis solution for use by forensic laboratories to generate mitochondrial DNA profiles for submission to the U.S. National DNA Index System CODIS database.
October 2019—Helmer Scientific launched its upright laboratory, pharmacy, and blood bank GX Solutions refrigerators, with models ranging from 13 to 56 cubic feet. GX Solutions are designed to keep temperatures within ±1°C throughout the unit, recover quickly from temperature changes after prolonged door openings, and maintain temperature stability.
October 2019—Menarini Silicon Biosystems launched its VRNxT, a sample preparation instrument that automates volume reduction steps in rare cell analysis workflows.
October 2019—The FDA approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes. Victoza is the first noninsulin drug approved to treat type 2 diabetes in pediatric patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.
October 2019—Bio-Rad Laboratories received FDA 510(k) clearance for its IH-500, an automated random access system for blood typing and screening, designed for small to medium-size laboratories. The system can process Bio-Rad’s range of IH gel cards for ABO blood grouping, reverse testing, phenotyping, Rh subgroups, antibody screening, antibody identification, single antigen testing, direct AHG testing, and crossmatching. In a separate release, the company announced FDA clearance for its BioPlex 2200 Lyme Total Assay, a multiplex test method to aid in
September 2019—Clever Culture Systems announced FDA 510(k) clearance of its APAS Independence instrument and associated urine analysis module as a class II medical device. The APAS Independence automatically screens, interprets, and sorts culture plates and can process more than 200 culture plates at a time. The instrument sorts culture plates showing significant bacterial growth from those that do not, without the need for further microbiologist assistance, the company says.
